stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Shares outstanding
NewAmsterdam Pharma Company N.V.'s shares outstanding at the end of fiscal 2025 was $118.4M, up 25.5% from $94.4M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $124.1M. Over the past ten years it has ranged from $3.5M (fiscal 2021) to $118.4M (fiscal 2025) — the current reading is the highest in ten years. NewAmsterdam Pharma Company N.V. ranks 108th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $118.4M | 25.50% |
| FY2024 | $94.4M | 14.84% |
| FY2023 | $82.2M | 333.21% |
| FY2022 | $19.0M | 449.74% |
| FY2021 | $3.5M | 0.00% |
| FY2020 | $3.5M | (80.56%) |
| FY2020 | $17.8M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $124.1M | 0.62% |
| Jun 2026 | $123.4M | 1.36% |
| Mar 2026 | $121.7M | 2.78% |
| Dec 2025 | $118.4M | (0.48%) |
| 21 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | $543.0M |
| ADMA ADMA Biologics Inc compare | $225.8M |
| NAMS NewAmsterdam Pharma Company N.V. | $124.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | $111.7M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| XNCR Xencor, Inc. compare | $75.9M |
| PHVS Pharvaris N.V. compare | $68.1M |
| MBX MBX Biosciences, Inc. compare | $47.7M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement